Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

23.20
-0.9600-3.97%
Post-market: 23.800.6000+2.59%16:49 EDT
Volume:1.55M
Turnover:35.91M
Market Cap:2.77B
PE:-10.82
High:24.75
Open:24.60
Low:22.67
Close:24.16
52wk High:42.21
52wk Low:21.02
Shares:119.54M
Float Shares:90.76M
Volume Ratio:0.95
T/O Rate:1.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:4.39
PE(LYR):-13.48

Loading ...

Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Aug 06

NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe

Reuters
·
Aug 05

NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate

Benzinga Earnings
·
Aug 05

NewAmsterdam Pharma Q2 Net Loss Widens to USD 64.1 Million; Revenue Falls to USD 3.7 Million

Reuters
·
Aug 05

Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Dow Jones
·
Aug 05

Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval

Simply Wall St.
·
Aug 03

NewAmsterdam Pharma to Host Investor Day Webcast for Analysts, Investors

Reuters
·
Jul 29

Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)

TIPRANKS
·
Jul 27

Newamsterdam Pharma Says EU CHMP Backs Approval of Ubeslo, Evlarco Cholesterol Drugs

Reuters
·
Jul 27

Newamsterdam Says EU CHMP Backs Ubeslo, Evlarco Cholesterol Drugs for Approval

Reuters
·
Jul 26

Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)

TIPRANKS
·
Jul 25

Newamsterdam Pharma Says EMA Panel Backs EU Approval for Ubeslo, Evlarco Cholesterol Drugs

Reuters
·
Jul 24

Newamsterdam Pharma COO Douglas Kling Resigns, Effective Aug. 14

Reuters
·
Jul 23

Newamsterdam Pharma Chief Accounting Officer Louise Kooij Disposes of Ordinary Shares Worth $3.08 Million

Reuters
·
Jul 23

Newamsterdam Pharma Publishes Obicetrapib Alzheimer’s Prevention Research Presentation

Reuters
·
Jul 17

Vivani Stock Puts These Obesity And Diabetes Treatment Stocks On The Radar

Simply Wall St.
·
Jul 12

Did NewAmsterdam’s (NAMS) Alzheimer’s Biomarker Signal Just Recast Obicetrapib’s Dual-Disease Investment Narrative?

Simply Wall St.
·
Jul 09

Newamsterdam Pharma Grants 28,700 Inducement Share Options Priced at $35.17

Reuters
·
Jul 03

Newamsterdam Pharma to Present Obicetrapib Data for Early Alzheimer’s Prevention at AAIC 2026

Reuters
·
Jul 01